GC Genome (Ticker: 340450 KS) is a South Korean company specializing in clinical genome analysis and providing over 300 types of genetic testing services. GC Genome plans to list on the KOSDAQ on June 11, 2025, offering 4 million new shares at 10,500 won per share, raising 42 billion won (approximately $31 million USD). The company reportedly plans to use the IPO proceeds for research and development to expand cancer types and preemptive cancer diagnosis. GC Genome, a subsidiary of GC Biopharma, has a projected market capitalization of around 248.3 billion won (approximately $181 million USD) post-listing. Samsung Securities is listed as the underwriter.